Food noise
GLP-1 receptor activation supports appetite regulation and a feeling of fullness.
Quiet the food noise. Let the weight follow: slowly, steadily, for good.
Get startedRx only. Prescription required. Available only if a US-licensed clinician determines it is medically appropriate after evaluation. Not all visits result in a prescription.
1STEP 1 trial of FDA-approved semaglutide 2.4 mg with diet and exercise, 68 weeks. 2SELECT trial of semaglutide 2.4 mg in adults with heart disease and overweight. Compounded semaglutide was not studied in these trials; results vary.
Semaglutide mimics GLP-1, the hormone that tells your brain you’re full. Smaller portions start to feel like enough, cravings get quieter, and the scale finally moves in one direction.
Individuals shown are models.
GLP-1 receptor activation supports appetite regulation and a feeling of fullness.
Food leaves your stomach more slowly, keeping you fuller for longer after every meal.
Supports insulin release in response to meals.
Illustrations of how GLP-1 medicines work, not patient data.
Slide to your weight today to see what the average result from semaglutide’s landmark trial would look like for you.
That’s like setting down 6 bags of flour.
Based on the average 14.9% weight loss at 68 weeks in the STEP 1 trial of FDA-approved semaglutide 2.4 mg, with diet and exercise. Compounded semaglutide was not studied in that trial. Your results will vary.
Tap around the box. Every shipment comes with what you need, plus a care team to message if you have questions.
Five minutes. Goals, health history, current medications. No waiting room.
A US-licensed clinician confirms you’re a fit and prescribes a dose built for you.
Compounded by a 503A US pharmacy, shipped cold, refilled automatically.
Adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. A US-licensed clinician reviews your health history and confirms whether it’s right for you.
The most common are nausea, diarrhea, vomiting, constipation, and stomach discomfort, mostly while your dose is going up. Starting low and stepping up slowly helps. Serious side effects are rare but possible; see the safety information below, and message your care team anytime.
Yes. $199/month covers your medication at every dose, your supplies, and ongoing clinician care and messaging. Your first month is $79. No insurance needed, cancel anytime.
Both are once-weekly injections. Semaglutide acts on one gut hormone (GLP-1) and has the longest track record. Tirzepatide acts on two (GLP-1 and GIP) and led to more average weight loss in a head-to-head trial. Your clinician can help you pick; mention it in your intake if you’re curious.
No. A clinician prescribes only if treatment is medically appropriate for you. Not all visits result in a prescription.
Complete a 5-minute intake. A clinician reviews within 48 hours. First shipment in under a week.
US-licensed physicians · 503A compounding pharmacy · HIPAA compliant
Rx only. Prescription required. A clinician determines whether treatment is medically appropriate. Not all visits result in a prescription.
Important safety information. Semaglutide may cause thyroid C-cell tumors; in rodents it caused these tumors, and it is unknown whether it causes them in people. Do not use if you or a family member has had medullary thyroid carcinoma (MTC), or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Serious side effects can include pancreatitis, gallbladder problems, low blood sugar, kidney problems, serious allergic reactions, increased heart rate, and depression or thoughts of suicide. Common side effects include nausea, diarrhea, vomiting, constipation, stomach pain, headache, and fatigue. Not for use during pregnancy.
Compounded medication. Compounded semaglutide is prepared by a state-licensed 503A pharmacy for an individual patient based on a valid prescription. Compounded drugs are not FDA-approved, and the FDA does not verify their safety, effectiveness, or quality. Figures above come from trials of FDA-approved semaglutide 2.4 mg (Wegovy®): STEP 1 (Wilding et al., NEJM 2021; average 14.9% weight loss at 68 weeks, 86.4% lost at least 5%). SELECT (Lincoff et al., NEJM 2023) found 20% lower risk of major cardiovascular events in adults with heart disease. Wegovy® is a registered trademark of Novo Nordisk A/S; Tempo Meds is not affiliated with Novo Nordisk A/S. Individuals shown are models.